shlokn/autogkb huggingface dataset:
Article: Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis
Gene: CYP2D6
Variant/haplotype: CYP2D6 ultrarapid metabolizer
Drug(s): paroxetine
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2D6 ultrarapid metabolizer is associated with decreased steady-state concentration of paroxetine in people with Depressive Disorder, Major, Anxiety Disorders or Panic Disorder as compared to CYP2D6 normal metabolizer.
Notes: "we found that the paroxetine Css of PMs, IMs, and UMs were 2.50, 1.12, and 0.39 times that of EMs, respectively, with PM and UM effects being statistically significant (multiple linear regression, exponentiated β = 2.50, 95% CI: 1.08–5.76, P = 0.03; exponentiated β = 0.39, 95% CI: 0.15–0.97, P = 0.04, respectively)."
Article: Germline Polymorphisms as Biomarkers of Tumor Response in Colorectal Cancer Patients Treated with Anti-EGFR Monoclonal Antibodies: A Systematic Review and Meta-Analysis
Gene: EGFR
Variant/haplotype: rs2227983
Drug(s): cetuximab, panitumumab
Phenotype category: Efficacy
Significant: no
Association: Allele A is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele G.
Notes: Meta-analysis with 6 studies. This association was not significant after multiple testing correction. This variant was listed as rs11543848 in the original article. The authors did not provide the exact number of patients but stated that "the median number of patients per analysis was 110 (range 50 - 740)". Most definitions of response were variations of the RECIST criteria.
Article: Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis
Gene: CYP2B6
Variant/haplotype: CYP2B6 intermediate metabolizer
Drug(s): levonorgestrel
Phenotype category: Metabolism/PK
Significant: no
Association: CYP2B6 intermediate metabolizer is not associated with increased clearance of levonorgestrel in women with HIV Infections as compared to CYP2B6 normal metabolizer.
Notes: Study investigated the effect on steady-state drugs used to treat HIV or tuberculosis on the pharmacokinetics of single dose levonorgestrel. Analysis carried out in the cohort treated with efavirenz.; Intermediate metabolizers defined as having one of the following genotypes:; 1) rs3745274 GG, rs28399499 TT and rs4803419 TT; 2) rs3745274 GT, rs28399499 TT and rs4803419 CC; 3) rs3745274 GG, rs28399499 CT and rs4803419 CC; 4) rs3745274 GT, rs28399499 TT and rs4803419 CT; 5) rs3745274 GG, rs28399499 CT and rs4803419 CT
Article: Clinical Pharmacology of an Atrasentan and Docetaxel Regimen in Men with Hormone-Refractory Prostate Cancer
Gene: ORM2
Variant/haplotype: rs2250242
Drug(s): atrasentan
Phenotype category: Metabolism/PK
Significant: no
Association: Genotype AA is not associated with clearance of atrasentan in men with Prostatic Neoplasms as compared to genotypes AG + GG.
Notes: No significant difference in atrasentan apparent oral clearance was seen between the two genotype groups.
Article: Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the Genetics of Lipid-Lowering Drugs and Diet Network study
Gene: APOC3
Variant/haplotype: rs4520
Drug(s): fenofibrate
Phenotype category: Efficacy
Significant: no
Association: Genotypes CT + TT are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.
Notes: No significant difference in the change in plasma triglyceride (TG) or high-density lipoprotein (HDL) levels between genotypes was seen, after three weeks of treatment with fenofibrate.
Article: Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis
Gene: CYP2C19
Variant/haplotype: CYP2C19 normal metabolizer genotype
Drug(s): amoxicillin, clarithromycin, esomeprazole
Phenotype category: Efficacy
Significant: no
Association: CYP2C19 normal metabolizer is not associated with decreased clinical benefit to amoxicillin, clarithromycin and esomeprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer.
Notes: "In contrast, studies that used rabeprazole and esomeprazole showed no significant differences in the RR of failed eradication among the three genotypes"
Article: Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
Gene: CYP2D6
Variant/haplotype: CYP2D6*1, CYP2D6*5, CYP2D6*10
Drug(s): endoxifen
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2D6 *10/*10 + *5/*10 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*5.
Notes: Patients (pre- (83%) and postmenopausal (17%)) with ER and/or PR positive breast tumors, which received 20 mg tamoxifen daily. Patients taking CYP2D6 inhibitors were excluded. DNA extracted from blood and screened for the following: *2 (2850C>T; rs16947), *2A (–1584C>G), *3 (2549delA; rs35742686), *4 (1846G>A; rs3892097), *5 (CYP2D6del), *6 (1707delT; rs5030655), *7 (2935A>C; rs5030867), *8 (1758G>T), *9 (2615-2617delAAG; rs5030656), *10 (100C>T; rs1065852), *12 (124G>A; rs5030862), *14 (1758G>A), *17 (1023C>T; rs28371706), *29 (1659G>A; rs61736512), *41 (2988G>A; rs28371725) and *xN (dup). Also gene-dose dependent effect for CYP2D6*5 and *10 genotype vs *1/*1 for metabolic ratio of endoxifen/N-desmethyltamoxifen.  [pre-menopausal][post-menopausal] [adjuvant] [DNA source: blood]
Article: Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE Study
Gene: SV2C
Variant/haplotype: rs6874435
Drug(s): olanzapine
Phenotype category: Efficacy
Significant: no
Association: Genotype AA is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AG + GG.
Notes: Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.
Article: Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites
Gene: ABCG2
Variant/haplotype: rs2231142
Drug(s): rosuvastatin
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.
Notes: "The mean Css/D of RST and its metabolites were significantly higher in the subjects carrying the ABCG2 421A than in non-carriers of this; allele. The effects of this allele remained significant after being adjusted by the baseline characteristics and false discovery rate; (FDR) (Padj < 0.01, FDR < 0.05)."
Article: Association of Genetic Variants With Response to Anti–Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration
Gene: CRHR1
Variant/haplotype: rs242939
Drug(s): bevacizumab, ranibizumab
Phenotype category: Efficacy
Significant: no
Association: Allele C is not associated with response to bevacizumab and ranibizumab in people with as compared to allele T.
Notes: The authors performed GWAS in a discovery cohort, and did a replication analysis.
Article: The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population
Gene: ABCB1
Variant/haplotype: rs1128503
Drug(s): clopidogrel
Phenotype category: Efficacy
Significant: yes
Association: Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.
Notes: Patients with genotype GG showed decreased platelet inhibtion compared to genotypes AA+AG. The authors than link increased platelet inhibition to increased resistance to clopidogrel.
Article: CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
Gene: ABCB1
Variant/haplotype: rs1045642
Drug(s): sirolimus, tacrolimus
Phenotype category: Metabolism/PK
Significant: no
Association: Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.
Notes: No associations with tacrolimus or sirolimus pharmacokinetic parameters were seen for this SNP. Please note that alleles have been complemented to the plus chromosomal strand.
Article: Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study
Gene: MYO1H
Variant/haplotype: rs7959663
Drug(s): lithium
Phenotype category: Efficacy
Significant: yes
Association: Allele C is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.
Article: Association between the rs7583431 single nucleotide polymorphism close to the activating transcription factor 2 gene and the analgesic effect of fentanyl in the cold pain test
Gene: ATF2
Variant/haplotype: rs1982235
Drug(s): fentanyl
Phenotype category: Dosage
Significant: no
Association: Allele G is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele T.
Article: CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
Gene: CYP2C19
Variant/haplotype: CYP2C19*1, CYP2C19*17
Drug(s): pantoprazole
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2C19 *17 is associated with increased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1.
Notes: There were 6 *17/*17 (TT) and 6 *1/*1 (CC). The study was done using pantoprazole. *1/*17 (n = 6) had concentration-time curves similar to *1/*1 subjects (typed only for *2 and *17).
Article: Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer
Gene: ABCB1
Variant/haplotype: rs2032582
Drug(s): dactinomycin
Phenotype category: Metabolism/PK
Significant: no
Association: Allele A is not associated with clearance of dactinomycin in children with Neoplasms.
Notes: No significant difference in actinomycin D clearance was seen between the genotypes (CC, AC, AA, CT, AT). Please note that alleles have been complemented to the plus chromosomal strand.
Article: Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users
Gene: CYP2C9
Variant/haplotype: CYP2C9*1, CYP2C9*2
Drug(s): warfarin
Phenotype category: Dosage
Significant: yes
Association: CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.
Notes: in European americans, but not African americans.
Article: CYP2C9 Genotype and Pharmacodynamic Responses to Losartan in Patients with Primary and Secondary Kidney Diseases
Gene: CYP2C9
Variant/haplotype: CYP2C9*1, CYP2C9*2, CYP2C9*3
Drug(s): losartan
Phenotype category: Efficacy
Significant: yes
Association: CYP2C9 *1/*3 is associated with decreased response to losartan in people with Kidney Diseases as compared to CYP2C9 *1/*1.
Notes: Patients with secondary kidney diseases carrying CYP2C9 variant alleles (*2 or *3) showed increases in blood pressure (both systolic and diastolic) as compared to patients with the *1/*1 genotype. A nonsignificant trend towards improved urinary protein excretion was seen in patients with primary kidney diseases with the *1/*1 genotype as compared to patients carrying variant alleles (*2 or *3).
Article: Association and cis-mQTL analysis of variants in CHRNA3-A5, CHRNA7, CHRNB2, and CHRNB4 in relation to nicotine dependence in a Chinese Han population
Gene: CHRNB4
Variant/haplotype: rs1948
Drug(s): nicotine
Phenotype category: Other
Significant: no
Association: Allele A is not associated with exposure to nicotine in men as compared to allele G.
Notes: No significant association between this allele and status as a smoker or non-smoker.
Article: The largest prospective warfarin-treated cohort supports genetic forecasting
Gene: CYP2C19
Variant/haplotype: rs3814637
Drug(s): warfarin
Phenotype category: Dosage
Significant: yes
Association: Allele C is associated with dose of warfarin.
Notes: This SNP explained 0.7% (P = 2.2 x 10(-6)) of the variation in warfarin dose.  The direction of the allele:dose relationship is not given.
Article: Genetic variants in NECTIN4 encoding an adhesion molecule are associated with continued opioid use
Gene: NECTIN4
Variant/haplotype: rs11265549
Drug(s): methadone
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotype AA is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.
Notes: rs11265549 was found to be in high linkage disequilibrium with rs3892375 and rs12116949 and was selected to be the tag SNP for all three variants.
Article: Effects of rs958804 and rs7858836 single‐nucleotide polymorphisms of the ASTN2 gene on pain‐related phenotypes in patients who underwent laparoscopic colectomy and mandibular sagittal split ramus osteotomy
Gene: ASTN2
Variant/haplotype: rs958804
Drug(s): fentanyl
Phenotype category: Dosage
Significant: yes
Association: Genotypes CC + CT are associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype TT.
Notes: This variant was found to be in moderate LD with rs7858836. p<0.025 was considered to be statistically significant.
Article: The Association of Transporter Genes Polymorphisms and Lung Cancer Chemotherapy Response
Gene: AQP2
Variant/haplotype: rs10875989
Drug(s): platinum
Phenotype category: Efficacy
Significant: no
Association: Allele T is not associated with response to platinum in people with Lung Neoplasms as compared to allele C.
Notes: 26 SNPs were selected which satisfied the following criteria: 1) SNPs were from HapMap Project Phase II of the Han Chinese population 2) were haplotype tagger SNPs 3) SNP minor allele frequency was higher than 5% in Han Chinese 4) the pairwise linkage disequilibrium correlation coefficient (r-squared) was greater than 0.8. After Bonferroni corrections no SNPs remained significantly associated with platinum drug efficacy.
Article: Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population
Gene: CYP3A5
Variant/haplotype: CYP3A5*1, CYP3A5*3, CYP3A5*6
Drug(s): fentanyl
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP3A5 *1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with decreased clearance of fentanyl in children as compared to CYP3A5 *1/*1 (assigned as normal metabolizer phenotype) .
Article: Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
Gene: CYP2D6
Variant/haplotype: CYP2D6*1, CYP2D6*10
Drug(s): haloperidol
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.
Notes: Patients with the *10 allele showed significantly higher plasma concentration:dose ratios of haloperidol as compared to patients with the *1 allele. When stratified for dose, this association was seen only in patients receiving less than 20mg/day (P=.003). In patients receiving 20mg/day or more, the association with CYP2D6 genotype no longer existed (P=.667). No association was seen between CYP2D6 genotype and plasma concentration:dose ratios of reduced haloperidol. CYP2D6*5 alleles were not included in statistical analysis due to low sample size.
Article: Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19
Gene: CYP2C9
Variant/haplotype: rs762081829
Drug(s): tolbutamide
Phenotype category: Metabolism/PK
Significant: yes
Association: Allele T is associated with decreased clearance of tolbutamide as compared to allele C.
Notes: In vitro analysis showed that intrinsic clearance of tolbutamide by CYP2C9 protein containing the T allele was 23% of that of the WT protein. Variant referred to as 218 C>T in the paper.
Article: Genome-wide association study of patient and clinician rated global impression severity during antipsychotic treatment
Gene: PPA2
Variant/haplotype: rs2636697
Drug(s): risperidone
Phenotype category: Efficacy
Significant: yes
Association: Allele G is associated with decreased response to risperidone in people with Schizophrenia as compared to allele A.
Notes: The number of G alleles present in a patient was positively associated with CGI-S score. Please note that this variant is in high linkage disequilibrium with rs2636719.
Article: Genetic variation in the Catechol-O-Methyltransferase (COMT) gene and morphine requirements in cancer patients with pain
Gene: COMT
Variant/haplotype: rs740603
Drug(s): morphine
Phenotype category: Dosage, Efficacy
Significant: yes
Association: Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.
Notes: This was for alleviation of pain from cancer.  The association was as part of a haplotype consisting of 11 rsIDs (the other rsIDs are rs2075507,rs7287550, rs5746849, rs737866, rs6269, rs2239393, rs4818, rs4680, rs174699, rs165728).  The haplotype was associated with a dose reduction factor of 0.71 .  Authors state that because the SNPs are linked, a strict Bonferroni correction is too conservative; however, that is what has been done here for p value.  Also noted was that the carriers of haplotype 1 have had the cancer diagnosis longer than have carriers of other haplotypes, and so the true difference in morphine requirements may be even greater than observed here.
Article: Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin
Gene: UGT1A1
Variant/haplotype: UGT1A1*28
Drug(s): fluorouracil, irinotecan, leucovorin
Phenotype category: Efficacy, Toxicity
Significant: no
Association: UGT1A1 *28 is not associated with decreased clinical benefit to fluorouracil, irinotecan and leucovorin in people with Neuroendocrine Tumors.
Notes: "We also found no differences in the efficacy or toxicity profile of patients based on their UGT1A1*28 status."
Article: A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform
Gene: SULT1C4
Variant/haplotype: rs1402467
Drug(s): docetaxel, thalidomide
Phenotype category: Efficacy
Significant: yes
Association: Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.
Notes: (allele inferred by frequency comparison with dbSNP, actual base not listed in paper)
Article: CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
Gene: CYP2B6
Variant/haplotype: rs3745274
Drug(s): efavirenz
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotype TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.
Notes: CYP2B6*6 TT had 63% lower CL/F (CV=9%).
Article: Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes
Gene: CYP2B6
Variant/haplotype: rs28399499
Drug(s): efavirenz
Phenotype category: Metabolism/PK
Significant: yes
Association: Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.
Notes: A multivariate linear regression model that included CYP2A6 rs28399433, UGT2B7 rs2365062 and CYP2B6 rs28399499 explained 22% variance in efavirenz plasma concentrations. *Note: All participants were CYP2B6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or  rs3745274 T/rs28399499 C or rs28399499 CC).* Alleles have been complemented to the plus chromosomal strand.
Article: G Protein-Coupled Receptor Kinase 5 Gene Polymorphisms Are Associated with Postoperative Atrial Fibrillation Following Coronary Artery Bypass Graft Surgery in Patients Receiving Beta-Blockers
Gene: GRK5
Variant/haplotype: rs4752292
Drug(s): Beta Blocking Agents
Phenotype category: Efficacy
Significant: yes
Association: Allele T is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele G.
Notes: Single-nucleotide polymorphisms in 10 candidate genes were tested for association with atrial fibrillation after coronary artery bypass grafting despite perioperative beta blocker therapy. The authors did not clearly identify the rs4752292 risk allele; it is variously identified as A or T in the supplementary materials. It is here assumed to be T, because rs4752292 is annotated as a T > G variant. rs4752292 is in strong linkage disequilibrium with rs3740563.
Article: Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients
Gene: DCTD
Variant/haplotype: rs4742
Drug(s): ara-CTP
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotype GG is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.
Notes: Alleles complemented to plus chromosomal strand.
Article: Fixed dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
Gene: CDA
Variant/haplotype: rs2072671
Drug(s): capecitabine
Phenotype category: Metabolism/PK
Significant: no
Association: Allele C is not associated with metabolism of capecitabine in people with Breast Neoplasms as compared to allele A.
Notes: No significant differences in the area under the concentration-time curve from 0 to infinity (AUCinf) were seen between any of the genotypes (CC, AC, AA). Nor were any significant differences seen between these genotypes when considering the capecitabine metabolites 5'-DFCR, 5'-DFUR or 5'FU (5'-fluorouracil). Please note alleles have been complemented to the plus chromosomal strand.
Article: Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis
Gene: MICA
Variant/haplotype: rs1051792
Drug(s): Tumor necrosis factor alpha (TNF-alpha) inhibitors
Phenotype category: Efficacy
Significant: yes
Association: Genotype GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.
Notes: The association was significant at 3 months following treatment initiation, but significance was lost at the 6 month timepoint.
Article: Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism
Gene: CYP2A6
Variant/haplotype: CYP2A6*1, CYP2A6*4
Drug(s): nicotine
Phenotype category: Other, Metabolism/PK
Significant: no
Association: CYP2A6 *4 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.
Notes: Individuals with *4, *7, *10 alleles had impaired nicotine metabolism in this study. Statistics were comparing metabolism levels in Japanese and Korean subjects, rather than these alleles compared to wildtype.
Article: Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron
Gene: SLC19A1
Variant/haplotype: rs1051266
Drug(s): mirabegron
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotype TT is associated with decreased dose-adjusted trough concentrations of mirabegron in healthy individuals as compared to genotype CT.
Notes: Alleles complemented. "Lastly, a lower Cmax/DW was observed in the SLC19A1 rs1051266 A/A genotype compared to the A/G genotype (puv = 0.016) (Table 4). "